Brief: Palatin Initiates Enrollment In The Phase 2 Bremelanotide Breakout Study In Patients With Diabetic Kidney Disease
19/01/2023 12:36
Jan 19 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN INITIATES ENROLLMENT IN THE PHASE 2 BREMELANOTIDE
BREAKOUT STUDY IN PATIENTS WITH DIABETIC KIDNEY DISEASE
* PALATIN TECHNOLOGIES INC- BREAKOUT STUDY CURRENTLY EXPECTS
TO
INITIATE PATIENT DOSING IN JANUARY 2023
Source text for Eikon: ID:nPnfghhWa
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity